Prostate Cancer - Diagnostic and Therapeutic Advances 2011
DOI: 10.5772/26951
|View full text |Cite
|
Sign up to set email alerts
|

Prostate Specific Membrane Antigen as Biomarker and Therapeutic Target for Prostate Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(8 citation statements)
references
References 86 publications
(58 reference statements)
0
8
0
Order By: Relevance
“…The clinical success of immunotherapeutic approaches in prostate cancer has been limited to date, although a number of prostate lineage-specific antigens, such as prostate-specific membrane antigen (PSMA, also known as FOLH1), offer potential therapeutic targets. The biology of PSMA and its relevance as a tumorspecific antigen for mCRPC has been reviewed extensively (7)(8)(9). PSMA has been used as a target for the development of diagnostics (10) and for therapeutic mAbs (11)(12)(13)(14).…”
Section: Introductionmentioning
confidence: 99%
“…The clinical success of immunotherapeutic approaches in prostate cancer has been limited to date, although a number of prostate lineage-specific antigens, such as prostate-specific membrane antigen (PSMA, also known as FOLH1), offer potential therapeutic targets. The biology of PSMA and its relevance as a tumorspecific antigen for mCRPC has been reviewed extensively (7)(8)(9). PSMA has been used as a target for the development of diagnostics (10) and for therapeutic mAbs (11)(12)(13)(14).…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, PSMA expression was observed to decrease in the prostate cancer cell line, LNCap, when incubated with androgen dihydrotestosterone and, conversely, cells grown in androgen-stripped media displayed increased PSMA expression [34]. It is clear that increased expression and enzymatic activity of PSMA in aggressive tumors are telling of a selective advantage bestowed by PSMA upon tumor cells and this contributes to prostate carcinogenesis [35].…”
Section: Clinical Relevance Of Psmamentioning
confidence: 98%
“…Clinical trials with 99m Tc-labeled J591 established detection of primary prostate cancer, as well as prostate bed recurrence and distant metastases, again, including metastasis to bone [30,47]. Several other developed monoclonal antibodies (3/A12, 3/E7 and 3/F11) bind to different epitopes of PSMA [35]. A study using 64 Cu-3/A12 for PET imaging of prostate cancer xenograft showed a good tumor-to-background ratio [44].…”
Section: Psma As a Biomarkermentioning
confidence: 99%
“…29,30 In normal prostate, PSMA is generally present as a soluble protein in cytoplasm; however, during cancer progression, cells begin to express more PSMA as an insoluble membrane form, resulting in high PSMA expression in high-grade and metastatic PCa and making it a promising target for imaging and therapy. 21,29,[31][32][33] Little information is available regarding the mechanisms controlling the expression of this gene; however, PSMA loss of expression seems to be connected with cancer progression from androgen-dependent to the androgen-independent stage. This can be exemplarily observed in the metastatic cell lines PC-3 and LNCaP.…”
Section: Molecular Targeting Of Pca and Tumor Modelsmentioning
confidence: 99%